Pharma BD Deal Intelligence

Lantheus Holdings, Inc. / Life Molecular Imaging Ltd.

2024 · Asset Purchase · Complete

Lantheus acquired global rights from Life Molecular Imaging to the RM2 radiotheranostic pair targeting gastrin-releasing peptide receptor (GRPR), comprising the 177Lu-DOTA-RM2 radiotherapeutic and the 68Ga-DOTA-RM2 radiodiagnostic. Lantheus paid USD 35 million upfront plus undisclosed regulatory milestones and royalties, and stated it intends to initiate a Phase 1/2a study of 177Lu-DOTA-RM2 in prostate cancer in 2025 as an option for patients for whom PSMA-targeted therapy may be unsuitable.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2029 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2024 deals